Remdesivir

Common brands: Veklury, Dexamethasone 1.5 Mg, Dexamethasone, Dextenza, Dexycu

Top reporter: Gilead Sciences, Inc.

SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]Corticosteroid [EPC]Interleukin-6 Receptor Antagonist [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Glycopeptide Antibacterial [EPC]
13,177
Total Reports
7,922
Serious Reports
3,271
Death Reports
30
Reported Reactions
Death Report Ratio: High (24.82%)

Patient Demographics

Male
7,267
Female
4,892

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Remdesivir.

# Reaction Reports % of Total
1 OFF LABEL USE 2,229
16.2%
2 ALANINE AMINOTRANSFERASE INCREASED 934
6.8%
3 COVID-19 907
6.6%
4 DRUG INEFFECTIVE 763
5.5%
5 DEATH 756
5.5%
6 BRADYCARDIA 652
4.7%
7 ASPARTATE AMINOTRANSFERASE INCREASED 628
4.6%
8 ACUTE KIDNEY INJURY 624
4.5%
9 RESPIRATORY FAILURE 526
3.8%
10 COVID-19 PNEUMONIA 486
3.5%
11 LIVER FUNCTION TEST INCREASED 420
3.0%
12 CONDITION AGGRAVATED 379
2.8%
13 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 328
2.4%
14 PNEUMONIA 328
2.4%
15 BLOOD CREATININE INCREASED 321
2.3%
16 CARDIAC ARREST 286
2.1%
17 HYPOTENSION 280
2.0%
18 RENAL IMPAIRMENT 280
2.0%
19 SEPTIC SHOCK 273
2.0%
20 DYSPNOEA 257
1.9%
21 HYPOXIA 257
1.9%
22 MULTIPLE ORGAN DYSFUNCTION SYNDROME 231
1.7%
23 DRUG INTERACTION 222
1.6%
24 MATERNAL EXPOSURE DURING PREGNANCY 215
1.6%
25 PRODUCT USE IN UNAPPROVED INDICATION 212
1.5%
26 OXYGEN SATURATION DECREASED 208
1.5%
27 THERAPY CESSATION 205
1.5%
28 BRONCHOPULMONARY ASPERGILLOSIS 203
1.5%
29 ACUTE RESPIRATORY DISTRESS SYNDROME 186
1.3%
30 PYREXIA 184
1.3%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.